Oncosil Medical Ltd
ASX:OSL
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
AU |
Oncosil Medical Ltd
ASX:OSL
|
14.8m AUD | -0.9 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.6B USD | 23.8 | ||
US |
Danaher Corp
NYSE:DHR
|
195.1B USD | 17.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 29.1 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.4B USD | 16.9 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.4B CHF | 20.1 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 34.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | 28.4 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.6B USD | 17.5 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.7B USD | 31.3 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR | 33.4 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.